There could be light at the end of the tunnel for individuals battling melanoma cancer. CBS News reported that researchers conducted a study to develop a "potential skin cancer vaccine" from Merck and Moderna, and found some promising results.
According to Reuters, a combination of Moderna's experimental melanoma vaccine and Merck's immunotherapy Keytruda "cut the risk of skin cancer's recurrence or death by 44 percent compared with Keytruda alone in a mid-stage trial."
Moderna's trial shot uses the same mRNA vaccine technology that has played an integral role in the success of COVID-19 vaccines, and the combination with Keytruda "has the capacity to be a new paradigm in the treatment of cancer," Paul Burton, Moderna's chief medical officer said in an interview.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There were 157 melanoma patients involved in the ongoing clinical trial, and researchers noted side effects in 14.4 percent of the patients who received the drug-vaccine combo compared to 10 percent of people who were only administered Keytruda, writes Reuters.
CBS notes that the shares of both the pharmaceutical and biotech companies increased on Tuesday after researchers reported a positive outcome of the shots midway through the study.
-
Home Depots are the new epicenters of ICE raidsIn the Spotlight The chain has not provided many comments on the ongoing raids
-
Why does Trump keep interfering in the NYC mayoral race?Today's Big Question The president has seemingly taken an outsized interest in his hometown elections, but are his efforts to block Zohran Mamdani about political expediency or something deeper?
-
The pros and cons of banning cellphones in classroomsPros and cons The devices could be major distractions
-
SpaceX breaks Starship losing streak in 10th testspeed read The Starship rocket's test flight was largely successful, deploying eight dummy satellites during its hour in space
-
Rabbits with 'horns' sighted across Coloradospeed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's studySpeed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-offSpeed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet underseaSpeed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
Bacteria can turn plastic waste into a painkillerUnder the radar The process could be a solution to plastic pollution
-
Scientists want to regrow human limbs. Salamanders could lead the way.Under the radar Humans may already have the genetic mechanism necessary
-
New York plans first nuclear plant in 36 yearsSpeed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
